Mediwound (NASDAQ:MDWD) posted its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.15) by $0.03, Morningstar.com reports. Mediwound had a negative return on equity of 383.19% and a negative net margin of 18.43%. The company had revenue of $20.75 million during the quarter, compared to analysts’ expectations of $7.03 million.
NASDAQ MDWD traded down $0.21 on Wednesday, reaching $2.96. 200 shares of the stock traded hands, compared to its average volume of 191,506. The company has a current ratio of 3.99, a quick ratio of 3.79 and a debt-to-equity ratio of 0.40. The stock’s fifty day simple moving average is $3.25. The company has a market cap of $86.70 million, a P/E ratio of -6.12 and a beta of 0.49. Mediwound has a 12 month low of $2.55 and a 12 month high of $6.75.
A number of hedge funds and other institutional investors have recently modified their holdings of MDWD. ARK Investment Management LLC bought a new stake in Mediwound during the 2nd quarter valued at $325,000. Menta Capital LLC raised its position in Mediwound by 200.2% during the 1st quarter. Menta Capital LLC now owns 44,514 shares of the biopharmaceutical company’s stock valued at $223,000 after purchasing an additional 29,686 shares in the last quarter. Delek Group Ltd. bought a new stake in Mediwound during the 1st quarter valued at $141,000. Marshall Wace LLP bought a new stake in Mediwound during the 1st quarter valued at $93,000. Finally, Millennium Management LLC raised its position in Mediwound by 33.2% during the 4th quarter. Millennium Management LLC now owns 68,365 shares of the biopharmaceutical company’s stock valued at $278,000 after purchasing an additional 17,048 shares in the last quarter. 31.16% of the stock is owned by institutional investors and hedge funds.
Mediwound Company Profile
MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns in the European Union, Israel, and Argentina.
Recommended Story: What is a front-end load?
Receive News & Ratings for Mediwound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediwound and related companies with MarketBeat.com's FREE daily email newsletter.